Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
Absci's AI-driven drug discovery platform is intriguing but remains early-stage, with no commercialized assets and only one candidate in clinical trials. The company faces intense competition, high ...
The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
美股AI医药开发概念股盘后上涨，Certara盘后涨超25%，Schrodinger涨超18%，Recursion Pharmaceuticals涨超21%，Absci Corp涨超17%，查尔斯河涨超6%。消息面上，美国食品药品管理局（FDA）宣称，将在单抗等诸多药物方面逐步放弃动物试验路线，转而追求“更有效的人类相关研究方法”。（财联社） ...
Artificial intelligence (AI) is poised to reshape pharmaceutical research by addressing some of the industry's most persistent challenges: lengthy timelines, high development costs and substantial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results